Medigen, Inc.
Frederick, MD
- UEI
- MGLJHKGKWBL3
- CAGE
- 4XUZ4
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 8420 Gas House Pike S, Frederick, MD 21701, USA
- Website
- medigen-usa.com
- Employees
- 51-250
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| To develop a lassa fever vaccine | National Institute of Allergy and Infectious Diseases | $4,488,598 | |
| Safety and immunogenicity of novel, live-attenuated V4020 vaccine for venezuelan equine encephalitis (VEE) in healthy… | National Institute of Allergy and Infectious Diseases | $5,848,035 | |
| Novel chikungunya vaccine with rearranged genome | National Institute of Allergy and Infectious Diseases | $480,885 | |
| Evaluation/titration of RBV stock/VLP manufacture | National Institute of Allergy and Infectious Diseases | $15,640 | |
| Multivalent emergency vaccine against pandemic influenza | National Institute of Allergy and Infectious Diseases | $190,758 |
About Medigen, Inc.
Medigen, Inc. NA Division, a for-profit corporate entity headquartered in Frederick, Maryland, develops live-attenuated vaccines and vaccine platform technologies for biodefense and emerging infectious disease threats as a prime recipient of federal research grants and contracts under non-set-aside competitive procurements. The vendor operates almost exclusively as a prime recipient (95% of recent awards) and holds no federal contract vehicle seats; all work flows through direct awards from the National Institutes of Health, primarily the National Institute of Allergy and Infectious Diseases.
Medigen's capability portfolio centers on vaccine development and clinical evaluation for Category B pathogens and biodefense threats. Recent representative work includes a $2.181 million definitive contract awarded by NIAID on September 23, 2025, for development of a Lassa fever vaccine through Phase 1 or 2 clinical trials, running through September 2030 under cost-no-fee pricing and place of performance in Frederick, Maryland. A cooperative agreement from NIAID awarded March 1, 2022, supported safety and immunogenicity testing of a novel live-attenuated V4020 vaccine for Venezuelan equine encephalitis, with clinical evaluation running through February 2027 and using Medigen's proprietary iDNA infectious clone platform to improve vaccine genetic stability and reduce reversion risk. Earlier work includes National Cancer Institute grants and Department of Agriculture National Institute of Food and Agriculture awards for related viral vaccine and diagnostic development.
Customer concentration is heavily skewed to NIAID within the broader HHS/NIH ecosystem. NIAID accounts for 10 awards carrying $3 million in combined potential value and represents 100% of the top-customer coverage by both award count and potential value; the National Cancer Institute and USDA NIFA together account for the remaining potential value. Activity has been sparse but steady — one award per year from 2018 to 2020, then a two-year gap, then two awards in 2025 — with only one award (combined potential value not detailed in source) facing ultimate completion within the next twenty-four months. Medigen subcontracts minimally; the source names one grant sub-award placed with Saint Louis University in January 2025 for recombinant protein and VLP-encapsidated RNA vaccine design and production supporting in vitro and animal model testing.
SBA capabilities narrative
Vaccine development, biotechnology services
Quick answers
What is Medigen, Inc.'s UEI?
Medigen, Inc.'s Unique Entity ID (UEI) in SAM.gov is MGLJHKGKWBL3.
What is Medigen, Inc.'s CAGE code?
Medigen, Inc.'s CAGE code is 4XUZ4.
What is Medigen, Inc.'s primary NAICS code?
Medigen, Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Medigen, Inc. located?
Medigen, Inc.'s physical address in SAM.gov is 8420 Gas House Pike S, Frederick, MD 21701, USA.
Is Medigen, Inc. registered in SAM.gov?
Yes. Medigen, Inc.'s SAM.gov registration is active through April 22, 2027.
What is Medigen, Inc.'s most recent federal award?
Medigen, Inc.'s most recent federal contract award is To develop a lassa fever vaccine (75N93025C00034), from National Institute of Allergy and Infectious Diseases, on September 23, 2025.
On GovTribe
See Medigen, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors